NRBO vs. FLGC, GLTO, APM, BIVI, ORGS, KALA, GLYC, NNVC, NRSN, and INDP
Should you be buying NeuroBo Pharmaceuticals stock or one of its competitors? The main competitors of NeuroBo Pharmaceuticals include Flora Growth (FLGC), Galecto (GLTO), Aptorum Group (APM), BioVie (BIVI), Orgenesis (ORGS), KALA BIO (KALA), GlycoMimetics (GLYC), NanoViricides (NNVC), NeuroSense Therapeutics (NRSN), and Indaptus Therapeutics (INDP). These companies are all part of the "pharmaceutical preparations" industry.
Flora Growth (NASDAQ:FLGC) and NeuroBo Pharmaceuticals (NASDAQ:NRBO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, community ranking, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.
NeuroBo Pharmaceuticals has a net margin of 0.00% compared to NeuroBo Pharmaceuticals' net margin of -75.33%. NeuroBo Pharmaceuticals' return on equity of -60.26% beat Flora Growth's return on equity.
NeuroBo Pharmaceuticals received 14 more outperform votes than Flora Growth when rated by MarketBeat users. Likewise, 75.00% of users gave NeuroBo Pharmaceuticals an outperform vote while only 59.09% of users gave Flora Growth an outperform vote.
Flora Growth currently has a consensus price target of $7.00, indicating a potential upside of 446.88%. NeuroBo Pharmaceuticals has a consensus price target of $10.00, indicating a potential upside of 143.31%. Given NeuroBo Pharmaceuticals' higher probable upside, equities research analysts clearly believe Flora Growth is more favorable than NeuroBo Pharmaceuticals.
NeuroBo Pharmaceuticals has lower revenue, but higher earnings than Flora Growth.
In the previous week, NeuroBo Pharmaceuticals had 4 more articles in the media than Flora Growth. MarketBeat recorded 8 mentions for NeuroBo Pharmaceuticals and 4 mentions for Flora Growth. NeuroBo Pharmaceuticals' average media sentiment score of 1.15 beat Flora Growth's score of 0.00 indicating that Flora Growth is being referred to more favorably in the media.
Flora Growth has a beta of 2, indicating that its stock price is 100% more volatile than the S&P 500. Comparatively, NeuroBo Pharmaceuticals has a beta of -0.23, indicating that its stock price is 123% less volatile than the S&P 500.
36.0% of Flora Growth shares are held by institutional investors. Comparatively, 1.4% of NeuroBo Pharmaceuticals shares are held by institutional investors. 17.6% of Flora Growth shares are held by insiders. Comparatively, 0.5% of NeuroBo Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
Flora Growth beats NeuroBo Pharmaceuticals on 8 of the 13 factors compared between the two stocks.
Get NeuroBo Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for NRBO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NRBO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NeuroBo Pharmaceuticals Competitors List
Related Companies and Tools
